Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS ANGPTL3-LRx in Healthy Volunteers With Elevated Triglycerides and Participants With Familial Hypercholesterolemia
A Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of ISIS 703802, Targeting ANGPTL3, Administered Subcutaneously to Healthy Volunteers With Elevated Triglycerides and Subjects With Familial Hypercholesterolemia
Sponsor: Akcea Therapeutics
A PHASE1 clinical study on Familial Hypercholesterolemia and Hypertriglyceridemia, this trial is completed. The trial is conducted by Akcea Therapeutics and has accumulated 9 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Dec 2020 — Jan 2021 [monthly]
Completed PHASE1
Phase: PHASE1_PHASE2 → PHASE1
-
Feb 2020 — Dec 2020 [monthly]
Completed PHASE1_PHASE2
▶ Show 4 earlier versions
-
Nov 2019 — Feb 2020 [monthly]
Completed PHASE1_PHASE2
-
Jun 2018 — Nov 2019 [monthly]
Completed PHASE1_PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
Status: Recruiting → Completed
-
Jan 2017 — Mar 2018 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Nov 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Akcea Therapeutics
- Ionis Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .